- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| Do | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 19.12. | CELZ stock touches 52-week low at $2.11 amid market challenges | 1 | Investing.com | ||
| 11.12. | CELZ-Aktie erreicht 52-Wochen-Tief bei 2,21 US-Dollar | 2 | Investing.com Deutsch | ||
| 11.12. | CELZ stock touches 52-week low at $2.21 amid market challenges | 1 | Investing.com | ||
| 03.12. | CELZ stock touches 52-week low at $2.36 amid market challenges | 1 | Investing.com | ||
| 03.12. | CELZ-Aktie erreicht 52-Wochen-Tief bei 2,36 US-Dollar | - | Investing.com Deutsch | ||
| 18.11. | CELZ stock touches 52-week low at $2.49 amid market challenges | 1 | Investing.com | ||
| 18.11. | CELZ-Aktie erreicht 52-Wochen-Tief bei 2,49 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.11. | Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment | 63 | GlobeNewswire (Europe) | PHOENIX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology leader in regenerative medicine, is pleased to announce the successful completion... ► Artikel lesen | |
| 08.11. | Creative Medical Technology files to sell 0.83M shares of common stocks by selling shareholders | 1 | Seeking Alpha | ||
| 08.11. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.11. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | - | SEC Filings | ||
| 08.11. | CELZ stock touches 52-week low at $2.65 amid market challenges | 2 | Investing.com | ||
| 23.10. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.10. | Creative Medical Technology files for $50M mixed securities shelf | 3 | Seeking Alpha | ||
| 09.08. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 25.07. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.07. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program | 1 | GlobeNewswire (USA) | ||
| 10.07. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Provides Corporate Update | 98 | GlobeNewswire (Europe) | PHOENIX, July 10, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative... ► Artikel lesen | |
| 24.06. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin | 93 | GlobeNewswire (Europe) | PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES | 139,03 | 0,00 % | Neurocrine Announces Commercial Launch Of Crenessity In US | WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX), Friday announced the commercial launch of Crenessity in the U.S. for adult and pediatric patients with classic congenital adrenal... ► Artikel lesen | |
| AMGEN | 263,24 | -0,47 % | Spotlight on Amgen: Analyzing the Surge in Options Activity | ||
| BIOGEN | 149,90 | 0,00 % | BMO cuts rating on Merck and Biogen, on lack of near term catalyst | ||
| IDEXX LABORATORIES | 417,11 | 0,00 % | Jim Cramer on IDEXX Laboratories (IDXX): Is This Pet Stock Poised for a Comeback? | ||
| REGENERON PHARMACEUTICALS | 716,74 | +0,32 % | Regeneron Pharma: Phase 3 Trial With EYLEA HD 8 Mg Meets Primary Endpoint | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD or aflibercept injection 8 mg... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 123,37 | +1,21 % | Sarepta awarded $115.2M in Vyondys 53 patent case: report | ||
| MODERNA | 40,440 | 0,00 % | Moderna-Deutschland-Chef im Interview (2): "Onkologie ist ein bedeutendes Forschungsfeld für ... | Die Aktie von Moderna hat sich in den vergangenen Monaten alles andere als erfreulich entwickelt. Im Mai notierte das Papier noch über 170 Dollar. Mittlerweile steht seitdem ein Kursverlust von 77 Prozent... ► Artikel lesen | |
| QUANTUM-SI | 2,150 | 0,00 % | Quantum-Si präsentiert ProteoVue-Software für Proteinforschung | ||
| VAXCYTE | 85,78 | 0,00 % | Vaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia asset | ||
| GERON | 3,300 | 0,00 % | Geron Gets Positive CHMP Opinion For RYTELO In Transfusion-Dependent Anemia Due To Lower-Risk MDS | WASHINGTON (dpa-AFX) - Geron Corporation (GERN), a commercial-stage biopharmaceutical company, Friday said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,660 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 48,030 | +1,03 % | Evotec: COO-Abgang und Halozyme-Übernahmepläne | Dr. Craig Johnstone, COO von Evotec, verlässt das Unternehmen nach zwölf Jahren, während ein internes Team vorübergehend seine Aufgaben übernimmt. Parallel brodelt die Gerüchteküche um eine mögliche... ► Artikel lesen | |
| TEMPUS AI | 35,230 | 0,00 % | Tempus AI (NASDAQ:TEM) Shares Down 5.7% Following Insider Selling | ||
| GUARDANT HEALTH | 31,370 | 0,00 % | Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance | PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024.
Third Quarter... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 7,600 | 0,00 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen |
CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.
